China Sxt Pharmaceuticals Stock Forecast

Sell candidate since Nov 06, 2025 Loss -5.59%

The China Sxt Pharmaceuticals Inc. stock price gained 2.27% on the last trading day (Monday, 17th Nov 2025), rising from $1.32 to $1.35. During the last trading day the stock fluctuated 4.91% from a day low at $1.33 to a day high of $1.39. The price has been going up and down for this period, and there has been a -4.26% loss for the last 2 weeks. Volume fell on the last day by -142 thousand shares and in total, 257 thousand shares were bought and sold for approximately $346.87 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -14.38% during the next 3 months and, with a 90% probability hold a price between $1.02 and $1.51 at the end of this 3-month period.

SXTC Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, November 13, 2025, and so far it has risen 3.85%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The China Sxt Pharmaceuticals Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.35 and $1.44. A break-up above any of these levels will issue buy signals. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Support, Risk & Stop-loss for China Sxt Pharmaceuticals Inc. stock

China Sxt Pharmaceuticals Inc. finds support from accumulated volume at $1.32 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0650 between high and low, or 4.91%. For the last week the stock has had daily average volatility of 5.37%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (SXTC) For The Upcoming Trading Day Of Tuesday 18th

For the upcoming trading day on Tuesday, 18th we expect China Sxt Pharmaceuticals Inc. to open at $1.36, and during the day (based on 14 day Average True Range), to move between $1.29 and $1.41, which gives a possible trading interval of +/-$0.117 (+/-9.08%) up or down from last closing price. If China Sxt Pharmaceuticals Inc. takes out the full calculated possible swing range there will be an estimated 9.08% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.32 (2.22%) than the resistance at $1.42 (5.19%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is China Sxt Pharmaceuticals Inc. stock A Buy?

China Sxt Pharmaceuticals Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.674 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on November 18, 2025 - $1.36 ( 0.370%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk